NEXLETOL and NEXLIZET: Simple, once-daily dosing with the flexibility to be combined with other lipid-lowering medications for appropriate patients1,2
oral, nonstatin, ldl-c lowering
In combination with EXISTING lipid-lowering medications
Taken with or without food
No need to titrate
Lipid levels should be analyzed within 8 to 12 weeks after initiation of NEXLETOL or NEXLIZET.
NEXLETOL and NEXLIZET are appropriate for a range of patient types requiring added LDL-C lowering on top of maximally tolerated statin therapy1-7
Defined as acute coronary syndromes, a history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or PAD presumed to be of atherosclerotic origin
Patients with a family history of elevated LDL-C or premature CAD, and with LDL-C ≥190 mg/dL without lipid-lowering therapies
NEXLETOL and NEXLIZET do not require refrigeration for storage1,2
LDL-C=low-density lipoprotein cholesterol; ASCVD=atherosclerotic cardiovascular disease; HeFH=heterozygous familial hypercholesterolemia; MI=myocardial infarction; TIA=transient ischemic attack; PAD=peripheral arterial disease; CAD=coronary artery disease.
References: 1. NEXLETOL. Prescribing information. ESPERION Therapeutics, Inc.; 2020. 2. NEXLIZET. Prescribing information. ESPERION Therapeutics, Inc.; 2020. 3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-e350. 4. Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132(22):2167-2192. 5. Diagnosis & Management. The FH Foundation. Accessed February 19, 2020. https://thefhfoundation.org/diagnosis-management 6. Data on file. CSR 1002-040. October 2018. 7. Data on file. CSR 1002-053. January 2019.